Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan

本研究旨在评估日本出生队列PCV-7疫苗接种计划的“物有所值”。运用马尔可夫模型进行了成本-效果分析，计算了将该项目作为公共卫生项目开展的增量成本-效果比（ICER）。我们发现，从支付者的角度来看，QALY中的ICER约为7，000，000日元。通过采用WHO的分类，即如果ICER（QALY）为GDP的1 - 3倍，则干预措施是“成本效益”的，日本的PCV-7疫苗接种计划被认为是“成本效益”的。

This study aims to appraise the 'value for money' of PCV-7 vaccination programfor the birth cohort in Japan. We conducted a cost-effectiveness analysis with Markov model and calculated incremental cost-effectiveness ratio (ICER) of launching such program as a public health one. We found that ICERs in QALY were about \7,000,000 from the perspective of payers. By adopting WHO's classification that an intervention is 'cost-effective' if ICER (in QALY) is between 1 and 3 times of GDP as a criterion, PCV-7 vaccination program in Japan is concluded as "cost-effective.